SPTAN1, APC, and FGFR3 Mutation Status and APOBEC Mutation Signatures are Predictive of Mitomycin C Response in Non-muscle-invasive Bladder Cancer

Currently, no biomarkers of response to mitomycin C have been identified in non-muscle-invasive bladder cancer patients. Predictive biomarkers could improve the treatment outcome and eliminate adverse events from unnecessary treatment.To identify and validate predictive biomarkers of chemoresection with mitomycin C.The intervention group of a randomised controlled trial was identified for analyses. The study was conducted between January 2018...